Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Tessa G SteenbruggenMaartje van SeijenLiselore M JanssenMette S van RamshorstErik D van WerkhovenMarie-Jeanne T D F Vrancken PeetersJelle WesselingEsther H LipsGabe S SonkePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The RCB, NRI, and Neo-Bioscore can identify patients with HER2-positive breast cancer with minimal residual disease (i.e., RCB = 1, NRI ≥ 0.75, or Neo-Bioscore = 0-1) after NST who have similar 5-year RFI compared with patients with pCR.